Q2 Earnings Forecast for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Investment analysts at Leerink Partnrs upped their Q2 2025 EPS estimates for shares of Illumina in a note issued to investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings of $1.03 per share for the quarter, up from their previous estimate of $1.02. The consensus estimate for Illumina’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina’s FY2025 earnings at $4.45 EPS and Q4 2026 earnings at $1.43 EPS.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.96 by $0.01. The business had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. Illumina’s revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.98 earnings per share.

Several other analysts also recently issued reports on ILMN. Evercore ISI upped their price target on Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price for the company. in a research report on Friday, July 11th. Barclays reiterated an “underweight” rating and set a $85.00 price target (up previously from $77.00) on shares of Illumina in a report on Tuesday, June 24th. Citigroup cut shares of Illumina from a “hold” rating to a “strong sell” rating and reduced their price objective for the stock from $85.00 to $80.00 in a research note on Wednesday, July 9th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Illumina from $120.00 to $85.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $125.11.

Illumina Trading Down 1.8%

Shares of NASDAQ:ILMN opened at $96.14 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.48 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $15.22 billion, a PE ratio of -15.84, a P/E/G ratio of 1.91 and a beta of 1.36. Illumina has a 1 year low of $68.70 and a 1 year high of $156.66. The firm has a fifty day moving average price of $89.22 and a 200 day moving average price of $95.19.

Institutional Investors Weigh In On Illumina

A number of institutional investors have recently bought and sold shares of ILMN. Fourth Dimension Wealth LLC bought a new position in shares of Illumina during the 4th quarter worth about $40,000. Rise Advisors LLC raised its position in Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 224 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in Illumina during the fourth quarter worth about $48,000. Rakuten Securities Inc. lifted its stake in Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 270 shares during the period. Finally, Center for Financial Planning Inc. acquired a new stake in Illumina during the first quarter valued at approximately $33,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity at Illumina

In other news, CFO Ankur Dhingra acquired 6,100 shares of the stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer owned 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.